← FDA DRUG APPROVALS
FDA ANDA · ANDA205441
TRI-MILI
norgestimate and ethinyl estradiol
Sponsor: AUROBINDO PHARMA LTD
APPLICATION
ANDA205441
TYPE
ANDA
ORIGINAL APPROVAL
2016-07-06
LATEST ACTION
2023-10-16
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
TRI-MILIPrescription
ETHINYL ESTRADIOL 0.035MG,0.035MG,0.035MG, NORGESTIMATE 0.18MG,0.215MG,0.25MG · TABLET · ORAL-28
Approval history
2023-10-16Labeling · Supplement 5 · standardAP
2023-10-16Labeling · Supplement 4 · standardAP
2022-04-29Labeling · Supplement 3 · standardAP
2022-01-25Labeling · Supplement 1 · standardAP
2016-07-06UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.